Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Pembrolizumab |
| Synonyms | |
| Therapy Description |
Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib for RCC, and with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 93 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, CD274 (PD-L1)-expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, and in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MLH1 negative | rectum cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a preferred primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| NRAS mutant | melanoma | predicted - sensitive | Pembrolizumab | Clinical Study - Cohort | Actionable | In a clinical study, NRAS mutations were associated with higher 6-month objective response rate (53.3% vs. 19.6% without NRAS mutations; p=0.019) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma, however, progression-free survival and overall survival were similar between patients with and without NRAS mutations (PMID: 29973670). | 29973670 |
| MLH1 negative | endometrial carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a preferred second-line therapy for patients with recurrent or metastatic endometrial carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | endometrial carcinoma | sensitive | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (KEYNOTE-158) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 48% (38/79, 11 complete responses, 27 partial responses) in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial carcinoma, with a median progression-free survival of 13.1 months (PMID: 34990208; NCT02628067). | detail... 34990208 detail... |
| MLH1 negative | small intestine adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | small intestine adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | Squamous Cell Carcinoma of Unknown Primary | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for patients with squamous cell carcinoma of unknown primary with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | colorectal cancer | sensitive | Pembrolizumab | FDA approved | Actionable | In a Phase III (KEYNOTE-177) trial that supported FDA approval, Keytruda (pembrolizumab) treatment as first-line therapy significantly improved median progression-free survival (16.5 vs 8.2 mo, HR=0.60, p=0.0002) compared to chemotherapy in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) colorectal cancer (PMID: 33264544; NCT02563002). | 33264544 detail... |
| MLH1 negative | intrahepatic cholangiocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as primary therapy for patients with unresectable or metastatic intrahepatic cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), or as subsequent-line therapy (NCCN.org). | detail... |
| MSH6 negative | rectum cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a preferred primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | chondrosarcoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic chondrosarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | Advanced Solid Tumor | sensitive | Pembrolizumab | FDA approved | Actionable | In a combined analysis of 5 trials that supported FDA approval, Keytruda (pembrolizumab) therapy resulted in an objective response rate of 39.6% (59/149) in advanced solid tumor patients with high levels of microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 30787022; NCT01876511, NCT02460198, NCT01848834, NCT02054806, NCT02628067). | detail... 30787022 |
| BRAF V600E | lung non-small cell carcinoma | not predictive | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, non-small cell lung cancer patients harboring BRAF V600E did not demonstrate a significantly different response to treatment with either Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), compared to patients with BRAF non-V600E mutations, demonstrating an objective response rate of 25% (3/12) vs 33% (3/9) (p=1.0) and median progression-free survival of 3.7 months vs 4.1 months (p=0.37) (PMID: 29723688). | 29723688 |
| MSH6 negative | Advanced Solid Tumor | sensitive | Pembrolizumab | FDA approved | Actionable | In a combined analysis of 5 trials that supported FDA approval, Keytruda (pembrolizumab) therapy resulted in an objective response rate of 39.6% (59/149) in advanced solid tumor patients with high levels of microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 30787022; NCT01876511, NCT02460198, NCT01848834, NCT02054806, NCT02628067). | detail... 30787022 |
| MSH6 negative | osteosarcoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic osteosarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | germ cell cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as recurrence therapy for patients with germ cell tumors with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | neuroendocrine tumor | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for patients with locally advanced or metastatic well-differentiated, Grade 3 neuroendocrine tumors with mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PTEN positive | melanoma | sensitive | Pembrolizumab | Clinical Study - Cohort | Actionable | In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196). | 26645196 |
| JAK2 inact mut | melanoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon, leading to a loss of protein expression (PMID: 27433843). | 27433843 |
| MLH1 negative | Adenocarcinoma of Unknown Primary | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for patients with adenocarcinoma of unknown primary with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | chordoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic chordoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | prostate adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with advanced or metastatic prostate adenocarcinoma cancer with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | penile cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as subsequent-line systemic therapy for metastatic/recurrent penile cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PTEN dec exp | melanoma | decreased response | Pembrolizumab | Clinical Study - Cohort | Actionable | In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Keytruda (pembrolizumab), compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196). | 26645196 |
| TP53 mutant | lung non-small cell carcinoma | predicted - sensitive | Pembrolizumab | Clinical Study - Cohort | Actionable | In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). | 28039262 |
| TP53 mutant | lung non-small cell carcinoma | predicted - sensitive | Pembrolizumab | Clinical Study - Cohort | Actionable | In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096). | 31097096 |
| MLH1 negative | neuroendocrine tumor | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for patients with locally advanced or metastatic well-differentiated, Grade 3 neuroendocrine tumors with mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | vulva squamous cell carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with MSI high or dMMR (often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) vulva squamous cell carcinoma (NCCN.org). | detail... |
| MSH6 negative | esophageal cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) esophageal cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). | detail... |
| MSH6 negative | colon cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as preferred primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | chordoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic chordoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | gallbladder cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as primary therapy for patients with unresectable or metastatic gallbladder cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), or as subsequent-line therapy (NCCN.org). | detail... |
| MLH1 negative | ampulla of Vater adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | extrahepatic bile duct carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as primary therapy for patients with unresectable or metastatic extrahepatic cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), or as subsequent-line therapy (NCCN.org). | detail... |
| BRAF V600E | melanoma | decreased response | Pembrolizumab | Clinical Study | Actionable | In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828). | 30630828 |
| MLH1 negative | osteosarcoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic osteosarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | colorectal cancer | sensitive | Pembrolizumab | FDA approved | Actionable | In a Phase III (KEYNOTE-177) trial that supported FDA approval, Keytruda (pembrolizumab) treatment as first-line therapy significantly improved median progression-free survival (16.5 vs 8.2 mo, HR=0.60, p=0.0002) compared to chemotherapy in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) colorectal cancer (PMID: 33264544; NCT02563002). | 33264544 detail... |
| IDH1 wild-type PTEN mut | glioblastoma | resistant | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy, with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119). | 30742119 |
| MLH1 negative | esophageal cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) esophageal cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). | detail... |
| MSH6 negative | Adenocarcinoma of Unknown Primary | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for patients with adenocarcinoma of unknown primary with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | gallbladder cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as primary therapy for patients with unresectable or metastatic gallbladder cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), or as subsequent-line therapy (NCCN.org). | detail... |
| MSH6 negative | ovarian cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for patients with recurrent ovarian cancer with MSH6 deficiency (NCCN.org). | detail... |
| MLH1 negative | penile cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as subsequent-line systemic therapy for metastatic/recurrent penile cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | colon cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as preferred primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | intrahepatic cholangiocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as primary therapy for patients with unresectable or metastatic intrahepatic cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), or as subsequent-line therapy (NCCN.org). | detail... |
| MLH1 negative | ovarian cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for patients with recurrent ovarian cancer with MLH1 deficiency (NCCN.org). | detail... |
| MLH1 negative | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastroesophageal junction cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). | detail... |
| MSH6 negative | stomach cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) stomach cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). | detail... |
| MSH6 negative | pancreatic adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for advanced or metastatic pancreatic adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastroesophageal junction cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). | detail... |
| MSH6 negative | ampulla of Vater adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | Ewing sarcoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic Ewing sarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | testicular germ cell cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a third-line therapy for metastatic testicular germ cell cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | extrahepatic bile duct carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as primary therapy for patients with unresectable or metastatic extrahepatic cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), or as subsequent-line therapy (NCCN.org). | detail... |
| BRAF mut PTEN loss | melanoma | no benefit | Pembrolizumab | Preclinical | Actionable | In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). | 26645196 |
| BRAF mut IDH1 wild-type | glioblastoma | predicted - sensitive | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119). | 30742119 |
| MSH6 negative | Squamous Cell Carcinoma of Unknown Primary | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for patients with squamous cell carcinoma of unknown primary with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | prostate adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with advanced or metastatic prostate adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | testicular germ cell cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a third-line therapy for metastatic testicular germ cell cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Pembrolizumab | Guideline | Actionable | Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). | detail... |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). | 27225694 |
| FBXW7 R505C | melanoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a melanoma patient treated with Keytruda (pembrolizumab) demonstrated a response in all lesions except one, which was found to harbor FBXW7 R505C (PMID: 32371478). | 32371478 |
| BRAF V600K | melanoma | predicted - sensitive | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828). | 30630828 |
| MSH6 negative | chondrosarcoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic chondrosarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | germ cell cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as recurrence therapy for patients with germ cell tumors with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PTEN mutant | gastrointestinal system cancer | decreased response | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, patients with MSI high, dMMR gastrointestinal tumors including gastric (n=18), colorectal (n=17), cholangiocarcinoma (n=5), small intestine (n=2), pancreatic (n=2), and duodenal cancer (n=1) harboring PTEN mutations demonstrated a decreased objective response rate (21.4 vs 54.8%), overall survival (15.2 vs 25.7 mo), and progression-free survival (4.3 vs 15.6 mo) compared to PTEN-wild-type patients when treated with Keytruda (pembrolizumab) or Opdivo (nivolumab) (PMID: 33926917). | 33926917 |
| MSH6 negative | Ewing sarcoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic Ewing sarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | vulva squamous cell carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with MSI high or dMMR (often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) vulva squamous cell carcinoma (NCCN.org). | detail... |
| MLH1 negative | endometrial cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | 35690222 detail... |
| JAK1 Q503* | melanoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 419 days developed disease progression likely due to the secondary resistance mutation, JAK1 Q503* (PMID: 27433843). | 27433843 |
| MLH1 negative | pancreatic adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for advanced or metastatic pancreatic adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | endometrial carcinoma | sensitive | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (KEYNOTE-158) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 48% (38/79, 11 complete responses, 27 partial responses) in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial carcinoma, with a median progression-free survival of 13.1 months (PMID: 34990208; NCT02628067). | detail... detail... 34990208 |
| MSH6 negative | endometrial carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a preferred second-line therapy for patients with recurrent or metastatic endometrial carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | stomach cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) stomach cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). | detail... |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03267888 | Phase I | Pembrolizumab | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT04295863 | Phase I | Nivolumab Pembrolizumab | Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers | Recruiting | USA | 0 |
| NCT04253964 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | Recruiting | USA | 0 |
| NCT02579863 | Phase III | Pembrolizumab Dexamethasone Lenalidomide | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | Terminated | 0 | |
| NCT02212730 | Phase I | Pembrolizumab | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | Terminated | 0 | |
| NCT03065400 | Phase II | Pembrolizumab | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | Completed | USA | 0 |
| NCT04565496 | Phase II | Pembrolizumab | Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients (PEM-PRO) | Not yet recruiting | ITA | 0 |
| NCT03341143 | Phase II | Pembrolizumab | Fecal Microbiota Transplant (FMT) in Melanoma Patients | Active, not recruiting | USA | 0 |
| NCT05024318 | Phase II | Pembrolizumab | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER) | Not yet recruiting | 1 | |
| NCT03089606 | Phase II | Pembrolizumab | Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker | Active, not recruiting | USA | 0 |
| NCT03309878 | Phase Ib/II | Pembrolizumab Mogamulizumab + Pembrolizumab | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas | Active, not recruiting | USA | 0 |
| NCT02959463 | Phase I | Pembrolizumab | Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma | Active, not recruiting | USA | 0 |
| NCT02362997 | Phase II | Pembrolizumab | Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL | Active, not recruiting | USA | 0 |
| NCT04267848 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study | Recruiting | USA | 1 |
| NCT02872025 | Phase I | Pembrolizumab | Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS) | Recruiting | USA | 0 |
| NCT03322540 | Phase II | Pembrolizumab Epacadostat + Pembrolizumab | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | Completed | USA | ITA | ESP | CAN | 14 |
| NCT02591654 | Phase I | Pembrolizumab | MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma | Active, not recruiting | USA | 0 |
| NCT04214249 | Phase II | Cytarabine + Daunorubicin Cytarabine Cytarabine + Idarubicin Pembrolizumab Cytarabine + Daunorubicin + Pembrolizumab Cytarabine + Pembrolizumab Cytarabine + Idarubicin + Pembrolizumab | BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
| NCT03516708 | Phase Ib/II | Pembrolizumab Epacadostat Capecitabine + Oxaliplatin | Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | Recruiting | USA | 0 |
| NCT05071014 | Phase I | Pembrolizumab | A Study of Pembrolizumab and Cryoablation in People With Mesothelioma | Recruiting | USA | 0 |
| NCT03504163 | Phase II | Pembrolizumab | Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer | Recruiting | USA | 0 |
| NCT02886585 | Phase II | Pembrolizumab | Pembrolizumab In Central Nervous System Metastases | Recruiting | USA | 0 |
| NCT01876511 | Phase II | Pembrolizumab | Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | Completed | USA | 0 |
| NCT03568058 | Phase I | Pembrolizumab | Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | Active, not recruiting | USA | 0 |
| NCT04569461 | Phase II | Pembrolizumab | Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy (TALON) | Not yet recruiting | USA | 0 |
| NCT03273153 | Phase III | Pembrolizumab Atezolizumab + Cobimetinib | A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | Terminated | USA | ITA | FRA | ESP | DEU | BEL | 9 |
| NCT04913025 | Phase II | Pembrolizumab Nivolumab | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) | Recruiting | 1 | |
| NCT03092323 | Phase II | Pembrolizumab | A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) | Recruiting | USA | ITA | CAN | 1 |
| NCT02305186 | Phase Ib/II | Pembrolizumab Capecitabine | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | Recruiting | USA | 0 |
| NCT02541565 | Phase I | Pembrolizumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Rituximab | Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma | Completed | USA | 0 |
| NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Recruiting | USA | 0 |
| NCT04795661 | Phase II | Pembrolizumab | Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) | Recruiting | FRA | 0 |
| NCT04697576 | Phase I | Nivolumab Pembrolizumab Ipilimumab | Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma | Recruiting | USA | 0 |
| NCT02359565 | Phase I | Pembrolizumab | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas | Recruiting | USA | CAN | 0 |
| NCT04231526 | Phase II | Pembrolizumab | Pembrolizumab in Early Stage Colon Cancer | Recruiting | USA | 0 |
| NCT02818920 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab | Active, not recruiting | USA | 0 |
| NCT03419130 | Phase II | Pembrolizumab | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | Withdrawn | USA | 0 |
| NCT03727061 | Phase II | Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | Recruiting | USA | 0 |
| NCT02971956 | Phase II | Pembrolizumab | A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer | Active, not recruiting | USA | 0 |
| NCT03166254 | Phase I | Pembrolizumab | Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer | Withdrawn | 0 | |
| NCT03752333 | Phase II | Pembrolizumab | Trial of Pembrolizumab in Cancer of Unknown Primary (CUPem) | Recruiting | 1 | |
| NCT02740920 | Phase II | Pembrolizumab | Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker | Terminated | CAN | 0 |
| NCT02520154 | Phase II | Carboplatin + Paclitaxel Pembrolizumab | Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT03233724 | Phase Ib/II | Pembrolizumab | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | Recruiting | USA | 0 |
| NCT01822652 | Phase I | Cyclophosphamide Fludarabine Pembrolizumab | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | Active, not recruiting | USA | 0 |
| NCT04931979 | Phase II | Pembrolizumab | SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy (Pembro-SRT) | Not yet recruiting | DEU | 0 |
| NCT05518032 | Phase II | Pembrolizumab | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) | Not yet recruiting | USA | 0 |
| NCT04637594 | Phase III | Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Recruiting | USA | 0 |
| NCT03338959 | Phase Ib/II | Pembrolizumab | Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma | Recruiting | USA | 0 |
| NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
| NCT04701918 | Phase II | Pembrolizumab | Pembrolizumab And Cryoablation In Urothelial Carcinoma | Recruiting | USA | 0 |
| NCT02882282 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias | Active, not recruiting | USA | 0 |
| NCT04453046 | Phase I | Pembrolizumab | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | Recruiting | USA | 0 |
| NCT03197467 | Phase II | Pembrolizumab | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN) | Active, not recruiting | DEU | 0 |
| NCT03712605 | Phase III | Pembrolizumab | Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer | Recruiting | USA | 0 |
| NCT02437071 | Phase II | Pembrolizumab | Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients | Active, not recruiting | USA | 0 |
| NCT02954874 | Phase III | Pembrolizumab | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | Active, not recruiting | USA | CAN | 1 |
| NCT03932409 | Phase I | Pembrolizumab | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE) | Recruiting | USA | 0 |
| NCT02767934 | Phase II | Pembrolizumab | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
| NCT02132754 | Phase I | Pembrolizumab MK-4166 | Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | Completed | 0 | |
| NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 14 |
| NCT05191472 | Phase II | Pembrolizumab | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | Recruiting | USA | 0 |
| NCT03390504 | Phase III | Pembrolizumab Erdafitinib Docetaxel + Vinflunine | A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 19 |
| NCT02335411 | Phase II | Cisplatin + Fluorouracil + Pembrolizumab Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | Completed | 0 | |
| NCT03331731 | Phase II | Pembrolizumab | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH) | Recruiting | 2 | |
| NCT03085719 | Phase II | Pembrolizumab | Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN | Recruiting | USA | 0 |
| NCT02256436 | Phase III | Pembrolizumab | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | Completed | 0 | |
| NCT03087760 | Phase II | Pembrolizumab | Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT03244384 | Phase III | Pembrolizumab | Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer | Active, not recruiting | USA | 1 |
| NCT02673333 | Phase II | Pembrolizumab | Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma | Active, not recruiting | USA | 0 |
| NCT02358031 | Phase III | Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | Active, not recruiting | 0 | |
| NCT03582475 | Phase I | Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | Recruiting | USA | 0 |
| NCT04104893 | Phase II | Pembrolizumab | A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP) | Recruiting | USA | 0 |
| NCT03813836 | Phase II | Pembrolizumab | Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY) | Recruiting | 1 | |
| NCT05092360 | Phase III | Pembrolizumab ALKS 4230 Topotecan Paclitaxel Pegylated liposomal-doxorubicin Gemcitabine ALKS 4230 + Pembrolizumab | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7) | Recruiting | USA | CAN | 0 |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT02964559 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | Active, not recruiting | USA | 0 |
| NCT03804944 | Phase II | CDX-301 CDX-301 + Pembrolizumab Pembrolizumab | Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV) | Recruiting | USA | 0 |
| NCT02318771 | Phase I | Pembrolizumab | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer | Unknown status | USA | 0 |
| NCT02708641 | Phase II | Pembrolizumab | A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML | Completed | USA | 0 |
| NCT04098068 | Phase II | Pembrolizumab | Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) | Active, not recruiting | USA | 0 |
| NCT02609503 | Phase II | Pembrolizumab | Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin | Active, not recruiting | USA | 0 |
| NCT02658019 | Phase II | Pembrolizumab | Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | Completed | USA | 0 |
| NCT03666325 | Phase II | Pembrolizumab Cetuximab + Pembrolizumab | Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle) | Unknown status | ITA | 0 |
| NCT04454528 | Phase Ib/II | Pembrolizumab | BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer | Recruiting | USA | 0 |
| NCT03126630 | Phase Ib/II | Pembrolizumab Anetumab ravtansine + Pembrolizumab | Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | Active, not recruiting | USA | CAN | 0 |
| NCT02987166 | Phase I | Pembrolizumab | HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001) | Completed | USA | 0 |
| NCT03361865 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 11 |
| NCT03406858 | Phase II | Pembrolizumab | Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT03358472 | Phase III | Pembrolizumab Carboplatin + Fluorouracil Epacadostat + Pembrolizumab Cetuximab + Cisplatin | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | Active, not recruiting | USA | ITA | ESP | CAN | AUT | 9 |
| NCT02303990 | Phase I | Pembrolizumab | RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Completed | USA | 0 |
| NCT03765918 | Phase III | Pembrolizumab Cisplatin + Pembrolizumab Cisplatin | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | Recruiting | USA | FRA | ESP | DEU | CAN | BEL | AUT | 17 |
| NCT03374488 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma | Completed | USA | ITA | FRA | ESP | DEU | CAN | 12 |
| NCT02454179 | Phase II | Pembrolizumab Acalabrutinib | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT03277638 | Phase Ib/II | Pembrolizumab | Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT03844750 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab | Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery | Recruiting | USA | 0 |
| NCT02337491 | Phase II | Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab +/- Bevacizumab for Recurrent GBM | Completed | USA | 0 |
| NCT03007732 | Phase II | Pembrolizumab + SD-101 Pembrolizumab | Pembrolizumab in Combination With Intratumoral SD-101 Therapy | Active, not recruiting | USA | 0 |
| NCT02841748 | Phase II | Pembrolizumab | A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study | Active, not recruiting | USA | 0 |
| NCT04875195 | Phase II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | Active, not recruiting | USA | ITA | FRA | CAN | 7 |
| NCT03142334 | Phase III | Pembrolizumab | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 15 |
| NCT02564263 | Phase III | Pembrolizumab Docetaxel + Irinotecan + Paclitaxel | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | Completed | 0 | |
| NCT03897881 | Phase II | mRNA-4157 + Pembrolizumab Pembrolizumab | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) | Active, not recruiting | USA | 1 |
| NCT04082572 | Phase II | Pembrolizumab | Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers | Recruiting | USA | 0 |
| NCT03070392 | Phase II | Dacarbazine Ipilimumab Pembrolizumab Tebentafusp | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 7 |
| NCT02971748 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | Active, not recruiting | USA | 0 |
| NCT03099564 | Phase I | Pembrolizumab | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | Active, not recruiting | USA | 0 |
| NCT03996473 | Phase Ib/II | Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride | Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases | Active, not recruiting | USA | ESP | BEL | 1 |
| NCT05217446 | Phase II | Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) | Recruiting | USA | ITA | ESP | DEU | BEL | 4 |
| NCT02575404 | Phase I | Belapectin Pembrolizumab | GR-MD-02 Plus Pembrolizumab in Melanoma Patients | Active, not recruiting | USA | 0 |
| NCT04746924 | Phase III | Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab | A Study of BGB-A1217 With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Recruiting | USA | ITA | FRA | ESP | DEU | 12 |
| NCT03245489 | Phase I | Pembrolizumab | Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |
| NCT03820986 | Phase III | Lenvatinib + Pembrolizumab Pembrolizumab | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 11 |
| NCT05204160 | Phase II | Pembrolizumab | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy | Recruiting | USA | 0 |
| NCT04317534 | Phase II | Pembrolizumab | Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm | Recruiting | USA | 0 |
| NCT05539365 | Phase Ib/II | Pembrolizumab | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
| NCT04454489 | Phase II | Pembrolizumab | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition | Recruiting | USA | 0 |
| NCT01993719 | Phase II | Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide | Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma | Completed | USA | 0 |
| NCT02707666 | Phase I | Pembrolizumab Cisplatin + Pemetrexed Disodium | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | Recruiting | USA | 0 |
| NCT02775435 | Phase III | Carboplatin + Nab-paclitaxel Pembrolizumab Carboplatin + Paclitaxel | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | Active, not recruiting | 0 | |
| NCT03783078 | Phase III | Pembrolizumab | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 3 |
| NCT02702401 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Completed | 0 | |
| NCT03382899 | Phase II | Pegilodecakin + Pembrolizumab Pembrolizumab | Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) | Terminated | USA | 0 |
| NCT02535247 | Phase II | Pembrolizumab | Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma | Terminated | USA | 0 |
| NCT02611960 | Phase II | Pembrolizumab Capecitabine + Docetaxel + Gemcitabine | Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122) | Active, not recruiting | 0 | |
| NCT04938609 | Phase II | Pembrolizumab | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | Recruiting | USA | 0 |
| NCT03553836 | Phase III | Pembrolizumab | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 9 |
| NCT04134325 | Phase I | Nivolumab Pembrolizumab | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | Recruiting | USA | 0 |
| NCT04016116 | Phase II | Pembrolizumab + Ruxolitinib Pembrolizumab | Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | Withdrawn | USA | 0 |
| NCT05229614 | Phase II | Pembrolizumab | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC) | Not yet recruiting | ITA | DEU | 0 |
| NCT05197322 | Phase II | Pembrolizumab | NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) | Recruiting | 1 | |
| NCT02837042 | Phase II | Pembrolizumab | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | Terminated | USA | 0 |
| NCT02489357 | Phase I | Degarelix Pembrolizumab | Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer | Completed | USA | 0 |
| NCT04003610 | Phase II | Pembrolizumab + Pemigatinib Pembrolizumab Carboplatin + Gemcitabine Pemigatinib | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 8 |
| NCT03190213 | Phase II | Pembrolizumab | Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC) | Terminated | USA | 0 |
| NCT02600949 | Phase I | Pembrolizumab | Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma | Recruiting | USA | 0 |
| NCT02324582 | Phase I | Pembrolizumab | MK-3475/BCG in High Risk Superficial Bladder Cancer | Active, not recruiting | USA | 0 |
| NCT04323202 | Phase I | Pembrolizumab | Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N | Recruiting | USA | 0 |
| NCT03924895 | Phase III | Pembrolizumab | Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 18 |
| NCT03632941 | Phase II | Pembrolizumab AVX901 + Pembrolizumab AVX901 | A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | Recruiting | USA | 0 |
| NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | FRA | CAN | 1 |
| NCT02784171 | Phase II | Cisplatin + Pemetrexed Disodium Pembrolizumab | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | Active, not recruiting | ITA | FRA | CAN | 0 |
| NCT03087019 | Phase II | Pembrolizumab | Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Active, not recruiting | USA | 0 |
| NCT04827862 | Phase II | Pembrolizumab | RADVAX for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy | Recruiting | USA | 0 |
| NCT05239728 | Phase III | Pembrolizumab Belzutifan + Pembrolizumab | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 20 |
| NCT03432741 | Phase I | Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Recruiting | USA | 0 |
| NCT03279692 | Phase II | Pembrolizumab | Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma | Active, not recruiting | USA | 0 |
| NCT02268825 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers | Terminated | USA | 0 |
| NCT02530502 | Phase Ib/II | Temozolomide Pembrolizumab | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | Terminated | USA | 0 |
| NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
| NCT03753659 | Phase II | Pembrolizumab | IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | Recruiting | DEU | 0 |
| NCT02014636 | Phase I | Pazopanib Pembrolizumab | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) | Completed | USA | 1 |
| NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | ESP | 1 |
| NCT02999477 | Phase I | Pembrolizumab Nab-paclitaxel | A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer | Active, not recruiting | USA | 0 |
| NCT04602377 | Phase II | Pembrolizumab Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab | Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT) | Recruiting | FRA | 0 |
| NCT05496036 | Phase II | Pembrolizumab | Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (MCC) | Not yet recruiting | USA | 0 |
| NCT02581982 | Phase II | Pembrolizumab Paclitaxel | Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | Active, not recruiting | USA | 0 |
| NCT02289209 | Phase II | Pembrolizumab | Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | Recruiting | USA | 0 |
| NCT02467361 | Phase Ib/II | Nivolumab Pembrolizumab Ipilimumab Napabucasin | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers | Completed | USA | 0 |
| NCT02684292 | Phase III | Brentuximab vedotin Pembrolizumab | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) | Active, not recruiting | 0 | |
| NCT05406713 | Phase II | Pembrolizumab | Pembrolizumab in MIBC | Recruiting | USA | 0 |
| NCT03924869 | Phase III | Pembrolizumab | Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 16 |
| NCT03385226 | Phase II | Pembrolizumab | A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT) | Recruiting | 1 | |
| NCT02306850 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | Completed | USA | 0 |
| NCT03331562 | Phase II | Pembrolizumab Paricalcitol + Pembrolizumab | A SU2C Catalyst Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | Completed | USA | 0 |
| NCT03248570 | Phase II | Pembrolizumab | Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | Active, not recruiting | USA | 0 |
| NCT02559687 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | Completed | 0 | |
| NCT02603887 | Phase I | Pembrolizumab | Pembrolizumab for Smoldering Multiple Myeloma (SMM) | Active, not recruiting | USA | 0 |
| NCT02939651 | Phase II | Pembrolizumab | A Study of Pembrolizumab in Patients With Neuroendocrine Tumors | Completed | USA | 0 |
| NCT03815058 | Phase II | Pembrolizumab + RO7198457 Pembrolizumab | A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma. | Active, not recruiting | USA | ESP | DEU | BEL | 2 |
| NCT02337686 | Phase II | Pembrolizumab | Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
| NCT03867175 | Phase III | Pembrolizumab | Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib w TMZ for rGBM | Not yet recruiting | USA | 0 |
| NCT03316872 | Phase II | Pembrolizumab | Study of Pembrolizumab and Radiotherapy in Liver Cancer | Recruiting | CAN | 0 |
| NCT02343952 | Phase II | Pembrolizumab | Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | Active, not recruiting | USA | 0 |
| NCT03057613 | Phase II | Pembrolizumab | A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck | Completed | USA | 0 |
| NCT02940496 | Phase Ib/II | Pembrolizumab | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
| NCT02359851 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | Terminated | USA | 0 |
| NCT05155254 | Phase III | IO102-IO103 + Pembrolizumab Pembrolizumab | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | Recruiting | USA | FRA | ESP | DEU | BEL | 6 |
| NCT02560636 | Phase I | Pembrolizumab | Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB) | Recruiting | 1 | |
| NCT02453594 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | Active, not recruiting | 0 | |
| NCT03978624 | Phase II | Pembrolizumab Entinostat + Pembrolizumab | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | Recruiting | USA | 0 |
| NCT04069273 | Phase II | Paclitaxel + Ramucirumab Paclitaxel + Pembrolizumab + Ramucirumab Pembrolizumab | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) (SEQUEL) | Recruiting | USA | 0 |
| NCT03325101 | Phase Ib/II | Pembrolizumab | Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery | Active, not recruiting | USA | 0 |
| NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
| NCT02500121 | Phase II | Pembrolizumab | Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer | Completed | USA | 0 |
| NCT02771197 | Phase II | Fludarabine + Melphalan Pembrolizumab | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | Active, not recruiting | USA | 0 |
| NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
| NCT03515629 | Phase III | Cemiplimab + Ipilimumab Pembrolizumab | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | Completed | USA | ITA | 1 |
| NCT02678572 | Phase III | Dacarbazine Ipilimumab Melphalan Pembrolizumab | Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 2 |
| NCT02351739 | Phase II | Pembrolizumab Acalabrutinib | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer | Completed | USA | 0 |
| NCT02362048 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
| NCT03457948 | Phase II | Pembrolizumab Pembrolizumab + Yttrium-90 microsphere therapy | Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases | Recruiting | USA | 0 |
| NCT02546986 | Phase II | Azacitidine Pembrolizumab | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 1 |
| NCT02335424 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) | Completed | 0 | |
| NCT05185739 | Phase II | Lenvatinib + Pembrolizumab Lenvatinib Pembrolizumab | Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1) | Recruiting | 1 | |
| NCT04808999 | Phase II | Pembrolizumab | Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) | Recruiting | USA | 0 |
| NCT02451930 | Phase I | Necitumumab Pembrolizumab | A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | Completed | USA | FRA | ESP | 1 |
| NCT02581943 | Phase II | Paclitaxel Pembrolizumab Carboplatin | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT03316573 | Phase II | Pembrolizumab | A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas | Suspended | USA | 0 |
| NCT03620019 | Phase II | Denosumab + Pembrolizumab Pembrolizumab | Denosumab + Pembrolizumab in Patients With Stage IV Melanoma | Active, not recruiting | USA | 0 |
| NCT04166734 | Phase I | Pembrolizumab | Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME) | Recruiting | 1 | |
| NCT02658097 | Phase II | Pembrolizumab | A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | Active, not recruiting | USA | 0 |
| NCT05119296 | Phase II | Pembrolizumab | Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | Recruiting | USA | 0 |
| NCT02899793 | Phase II | Pembrolizumab | Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT05025813 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE) | Recruiting | 1 | |
| NCT02998268 | Phase II | Pembrolizumab Carboplatin + Paclitaxel | Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma | Active, not recruiting | USA | 0 |
| NCT02728830 | Phase I | Pembrolizumab | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | Active, not recruiting | USA | 0 |
| NCT03727880 | Phase II | Defactinib + Pembrolizumab Pembrolizumab | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
| NCT02892201 | Phase II | Pembrolizumab | Pembrolizumab in HNSCC With Residual Disease After Radiation | Active, not recruiting | USA | 0 |
| NCT04214067 | Phase III | Pembrolizumab | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | Active, not recruiting | USA | 1 |
| NCT02179918 | Phase I | Utomilumab Pembrolizumab | A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) | Completed | USA | 0 |
| NCT04754321 | Phase I | Pembrolizumab | Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer | Recruiting | USA | 0 |
| NCT03498612 | Phase II | Pembrolizumab | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Recruiting | USA | 0 |
| NCT02769520 | Phase II | Pembrolizumab | Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck | Active, not recruiting | USA | 0 |
| NCT02574533 | Phase I | Pembrolizumab FANG vaccine | Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma | Completed | USA | 0 |
| NCT04152863 | Phase II | Pembrolizumab Coxsackievirus A21 + Pembrolizumab | Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 6 |
| NCT03290079 | Phase II | Pembrolizumab | Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas | Suspended | USA | 0 |
| NCT02710396 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Genetic Predictors of Benefit to Pembrolizumab | Active, not recruiting | USA | 0 |
| NCT02858869 | Phase 0 | Pembrolizumab | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | Active, not recruiting | USA | 0 |
| NCT03302234 | Phase III | Pembrolizumab Ipilimumab + Pembrolizumab | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) | Completed | USA | ITA | FRA | ESP | DEU | CAN | 18 |
| NCT02949219 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT02287428 | Phase I | NeoVax Pembrolizumab Temozolomide NeoVax + Pembrolizumab + Temozolomide NeoVax + Pembrolizumab | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM | Recruiting | USA | 0 |
| NCT03395847 | Phase I | Pembrolizumab + Ramucirumab Pembrolizumab | A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma | Unknown status | USA | 0 |
| NCT03036488 | Phase III | Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 15 |
| NCT02625961 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) | Active, not recruiting | 0 | |
| NCT05341349 | Phase I | Ipilimumab + Nivolumab Pembrolizumab | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases | Not yet recruiting | USA | 0 |
| NCT02382406 | Phase Ib/II | Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | Active, not recruiting | USA | 0 |
| NCT04305054 | Phase Ib/II | Pembrolizumab + Vibostolimab Pembrolizumab | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B) | Recruiting | USA | ITA | FRA | ESP | 4 |
| NCT04089904 | Phase II | Pembrolizumab | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | Recruiting | USA | 0 |
| NCT02054806 | Phase I | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | Completed | 0 | |
| NCT03407170 | Phase II | Pembrolizumab | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | Terminated | USA | 0 |
| NCT04061590 | Phase II | Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
| NCT02642809 | Phase I | Pembrolizumab | Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers | Completed | USA | 0 |
| NCT04801966 | Phase 0 | Palbociclib Alpelisib Atezolizumab Vemurafenib Ribociclib Talazoparib Cobimetinib Trametinib Abemaciclib Dabrafenib Nivolumab Binimetinib Pembrolizumab Encorafenib | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR) | Recruiting | 1 | |
| NCT03210662 | Phase II | Pembrolizumab | Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL) | Recruiting | USA | 0 |
| NCT02563002 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab | Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | Active, not recruiting | 0 | |
| NCT03284424 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) | Active, not recruiting | USA | FRA | ESP | DEU | CAN | 5 |
| NCT02331368 | Phase II | Lenalidomide Melphalan Pembrolizumab | Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | Completed | USA | 0 |
| NCT02422381 | Phase Ib/II | Gemcitabine Pembrolizumab | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
| NCT03728972 | Phase II | Pembrolizumab | Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type | Recruiting | USA | 0 |
| NCT02085070 | Phase II | Pembrolizumab | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | Completed | USA | 0 |
| NCT05172258 | Phase II | Ipatasertib + Pembrolizumab Pembrolizumab | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | Recruiting | USA | 0 |
| NCT03319745 | Phase II | Pembrolizumab | A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy | Active, not recruiting | USA | 0 |
| NCT03291353 | Phase 0 | Pembrolizumab | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia | Withdrawn | USA | 0 |
| NCT02437370 | Phase I | Pembrolizumab Gemcitabine Docetaxel | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | Active, not recruiting | USA | 0 |
| NCT03197506 | Phase II | Pembrolizumab + Temozolomide Pembrolizumab | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | Recruiting | USA | 0 |
| NCT04895722 | Phase II | MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 5 |
| NCT03225664 | Phase Ib/II | Pembrolizumab Pembrolizumab + Trametinib | BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
| NCT03901378 | Phase II | Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | Withdrawn | USA | 0 |
| NCT03051672 | Phase II | Pembrolizumab | Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC | Terminated | USA | 0 |
| NCT03217071 | Phase II | Pembrolizumab | Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT04534205 | Phase II | BNT113 + Pembrolizumab Pembrolizumab | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) | Recruiting | USA | ITA | ESP | DEU | CAN | BEL | AUT | 6 |
| NCT02267603 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | Completed | USA | 0 |
| NCT02407171 | Phase Ib/II | Pembrolizumab | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | Suspended | USA | 0 |
| NCT02557321 | Phase Ib/II | PV-10 Pembrolizumab | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | Recruiting | USA | 1 |
| NCT04139317 | Phase II | Capmatinib + Pembrolizumab Pembrolizumab | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 >= 50% | Active, not recruiting | ITA | FRA | ESP | DEU | CAN | BEL | 10 |
| NCT02511184 | Phase I | Crizotinib Pembrolizumab | Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients | Terminated | USA | 0 |
| NCT02499835 | Phase Ib/II | Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT03430700 | Phase II | Pembrolizumab | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT) | Recruiting | 1 | |
| NCT02768792 | Phase II | Pembrolizumab | High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML | Active, not recruiting | USA | 0 |
| NCT03449238 | Phase Ib/II | Pembrolizumab | Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients | Recruiting | USA | 0 |
| NCT02963090 | Phase II | Pembrolizumab + Topotecan Pembrolizumab | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Terminated | USA | 0 |
| NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Active, not recruiting | USA | 0 |
| NCT04128696 | Phase III | Pembrolizumab GSK3359609 + Pembrolizumab | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 20 |
| NCT04977375 | Phase Ib/II | Pembrolizumab | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT03486873 | Phase III | Pembrolizumab | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 40 |
| NCT03035331 | Phase Ib/II | Pembrolizumab | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
| NCT02981914 | Phase 0 | Pembrolizumab | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | Recruiting | USA | 0 |
| NCT03379441 | Phase II | Pembrolizumab | Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC) | Not yet recruiting | ITA | 0 |
| NCT03255018 | Phase II | Pembrolizumab | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas | Active, not recruiting | USA | 0 |
| NCT02411656 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | Recruiting | USA | 0 |
| NCT03325166 | Phase II | Pembrolizumab | Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases | Terminated | USA | 0 |
| NCT04046133 | Phase I | Pembrolizumab | Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus (CORINTH) | Recruiting | 2 | |
| NCT04622007 | Phase II | Pembrolizumab Pembrolizumab + Tomivosertib | Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy (KICKSTART) | Recruiting | USA | 0 |
| NCT02787005 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199) | Completed | 0 | |
| NCT02408042 | Phase Ib/II | Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | Withdrawn | USA | 0 |
| NCT02252042 | Phase III | Pembrolizumab Methotrexate Cetuximab Docetaxel | Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) | Completed | 0 | |
| NCT02339324 | Phase I | Interferon alpha-2b Pembrolizumab | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | Completed | USA | 0 |
| NCT02142738 | Phase III | Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | Completed | 0 | |
| NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Recruiting | USA | 0 |
| NCT02359019 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy | Active, not recruiting | USA | 0 |
| NCT04380636 | Phase III | Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 18 |
| NCT04708418 | Phase II | Pembrolizumab Pembrolizumab + Vidutolimod | A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma | Recruiting | USA | 0 |
| NCT05430009 | Phase I | Pembrolizumab | Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT05352672 | Phase III | Cemiplimab Cemiplimab + Fianlimab Pembrolizumab | Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | Recruiting | USA | 1 |
| NCT03771820 | Phase II | Pembrolizumab NC-6004 + Pembrolizumab | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | Recruiting | 8 | |
| NCT02635360 | Phase II | Cisplatin Pembrolizumab | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | Active, not recruiting | USA | 0 |
| NCT03725059 | Phase III | Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Epirubicin + Paclitaxel Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | Active, not recruiting | USA | FRA | ESP | DEU | CAN | BEL | 18 |
| NCT04475939 | Phase III | Pembrolizumab Niraparib + Pembrolizumab | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 21 |
| NCT03287050 | Phase I | Pembrolizumab | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma | Terminated | USA | 0 |
| NCT04946370 | Phase Ib/II | Pembrolizumab 225Ac-J591 + Pembrolizumab | Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC | Recruiting | USA | 0 |
| NCT04657991 | Phase III | Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Recruiting | USA | ITA | ESP | DEU | CAN | 9 |
| NCT02332668 | Phase Ib/II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Recruiting | USA | ITA | FRA | DEU | 6 |
| NCT04093167 | Phase II | Pembrolizumab | Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC | Active, not recruiting | USA | CAN | 0 |
| NCT02638090 | Phase Ib/II | Pembrolizumab Vorinostat | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
| NCT02365766 | Phase Ib/II | Cisplatin Pembrolizumab Gemcitabine | Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer | Active, not recruiting | USA | 0 |
| NCT03293680 | Phase II | Pembrolizumab | Pembrolizumab in Elderly Patients With Advanced Lung Cancer | Recruiting | ESP | 0 |
| NCT04241185 | Phase III | Pembrolizumab Cisplatin Mitomycin C Gemcitabine Fluorouracil | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | Recruiting | USA | ITA | FRA | ESP | 20 |
| NCT03661723 | Phase II | Bevacizumab Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
| NCT04166487 | Phase II | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium | Plasma-Adapted First-Line Pembro In NSCLC | Recruiting | USA | 0 |
| NCT04443348 | Phase II | Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab | Pre-op Pembro + Radiation Therapy in Breast Cancer | Recruiting | USA | 0 |
| NCT04318717 | Phase Ib/II | Pembrolizumab | Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma | Recruiting | USA | 0 |
| NCT02591615 | Phase II | Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | Active, not recruiting | USA | 0 |
| NCT03968419 | Phase II | Canakinumab Pembrolizumab Canakinumab + Pembrolizumab | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) | Completed | USA | FRA | ESP | DEU | CAN | BEL | 6 |
| NCT04032418 | Phase II | Pembrolizumab | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT04387084 | Phase I | Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | Recruiting | USA | 0 |
| NCT02576990 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170) | Completed | 0 | |
| NCT02494583 | Phase III | Capecitabine Cisplatin + Fluorouracil Pembrolizumab | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | Completed | 0 | |
| NCT03347617 | Phase II | Pembrolizumab | Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma | Active, not recruiting | USA | 0 |
| NCT04712851 | Phase II | Pembrolizumab | Pembrolizumab for the Treatment of High-Grade Vulvar, Vaginal, or Cervical Intraepithelial Neoplasia | Recruiting | USA | 0 |
| NCT02537444 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) | Completed | USA | 0 |
| NCT02830594 | Phase II | Pembrolizumab | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | Active, not recruiting | USA | 0 |
| NCT02506153 | Phase III | Interferon alpha-2b Pembrolizumab | High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | Active, not recruiting | USA | CAN | 1 |
| NCT03520686 | Phase III | ALT-803 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab ALT-803 + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab | QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. | Recruiting | USA | 0 |
| NCT03631199 | Phase III | Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 34 |
| NCT03366844 | Phase Ib/II | Pembrolizumab | Breast Cancer Study of Preoperative Pembrolizumab + Radiation | Active, not recruiting | USA | 0 |
| NCT04157985 | Phase III | Nivolumab Ipilimumab Pembrolizumab Atezolizumab | Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT03990961 | Phase II | Pembrolizumab | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting | USA | 0 |
| NCT03586024 | Phase Ib/II | Pembrolizumab | Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL) | Withdrawn | USA | 0 |
| NCT02880345 | Phase 0 | Pembrolizumab | RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy | Withdrawn | USA | 0 |
| NCT04683679 | Phase II | Olaparib + Pembrolizumab Pembrolizumab | A Study of Radiation Therapy With Pembrolizumab and Olaparib in Women Who Have Triple-Negative Breast Cancer | Recruiting | USA | 0 |
| NCT02440425 | Phase II | Paclitaxel Pembrolizumab | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT02263508 | Phase Ib/II | Pembrolizumab Talimogene laherparepvec | MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 13 |
| NCT03397654 | Phase Ib/II | Pembrolizumab | Study of Pembrolizumab Following TACE in Primary Liver Carcinoma (PETAL) | Recruiting | 1 | |
| NCT02220894 | Phase III | Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | Completed | 0 | |
| NCT04009967 | Phase II | Pembrolizumab | Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01) | Recruiting | CAN | 0 |
| NCT02555657 | Phase III | Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | Completed | 0 | |
| NCT03391973 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) | Recruiting | CAN | 0 |
| NCT03091478 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Leptomeningeal Disease | Terminated | USA | 0 |
| NCT03891979 | FDA approved | Ciprofloxacin Metronidazole Pembrolizumab | Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma | Withdrawn | USA | 0 |
| NCT03832569 | Phase II | Pembrolizumab | Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors | Recruiting | USA | 0 |
| NCT02332980 | Phase II | Pembrolizumab | A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
| NCT02311582 | Phase Ib/II | Pembrolizumab | MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas | Active, not recruiting | USA | 0 |
| NCT02447003 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | Completed | 0 | |
| NCT04220866 | Phase II | Pembrolizumab + Ulevostinag Pembrolizumab | Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) | Active, not recruiting | USA | FRA | ESP | AUT | 6 |
| NCT04303169 | Phase Ib/II | Pembrolizumab Pembrolizumab + Vibostolimab Coxsackievirus A21 + Pembrolizumab | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C) | Recruiting | USA | ITA | FRA | 3 |
| NCT02650999 | Phase Ib/II | Pembrolizumab | Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas | Completed | USA | 0 |
| NCT03428802 | Phase II | Pembrolizumab | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | Recruiting | USA | 0 |
| NCT02690948 | Phase II | Pembrolizumab + Vismodegib Pembrolizumab | Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer | Completed | USA | 0 |
| NCT02684461 | Phase II | Pembrolizumab | Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel | Completed | USA | 0 |
| NCT04624204 | Phase III | Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 18 |
| NCT04129515 | Phase Ib/II | Pembrolizumab | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | Not yet recruiting | USA | 0 |
| NCT04581382 | Phase I | Pembrolizumab Nivolumab | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | Recruiting | USA | 0 |
| NCT03383094 | Phase II | Pembrolizumab Cisplatin + Radiotherapy | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | Recruiting | USA | 0 |
| NCT04274907 | Phase I | Pembrolizumab + Venetoclax Pembrolizumab | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression | Terminated | USA | 0 |
| NCT02296684 | Phase II | Pembrolizumab Cisplatin | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT03829332 | Phase III | Pembrolizumab Lenvatinib + Pembrolizumab | Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naive Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007) | Active, not recruiting | USA | ITA | FRA | CAN | 15 |
| NCT02919969 | Phase II | Pembrolizumab | Pembrolizumab in Refractory Metastatic Anal Cancer | Active, not recruiting | USA | 0 |
| NCT03425643 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 18 |
| NCT02853344 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | Completed | 0 | |
| NCT05215340 | Phase III | Pembrolizumab Datopotamab Deruxtecan + Pembrolizumab | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) | Recruiting | USA | ESP | 7 |
| NCT02755272 | Phase II | Pembrolizumab Carboplatin + Gemcitabine | A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
| NCT05204290 | Phase I | Pembrolizumab | A Pilot Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab | Recruiting | USA | 0 |
| NCT04969861 | Phase II | NKTR-214 + Pembrolizumab Pembrolizumab | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | Terminated | USA | ITA | FRA | AUT | 5 |
| NCT03259867 | Phase II | Nivolumab Pembrolizumab | Combination of TATE and PD-1 Inhibitor in Liver Cancer | Recruiting | USA | 0 |
| NCT05323656 | Phase II | Pembrolizumab Pembrolizumab + Setanaxib | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic SCCHN | Recruiting | USA | FRA | ESP | 0 |
| NCT03898180 | Phase III | Lenvatinib + Pembrolizumab Pembrolizumab | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 14 |
| NCT02316002 | Phase II | Pembrolizumab | Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT04671667 | Phase II | Cisplatin Pembrolizumab Carboplatin | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT04533451 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT02853305 | Phase III | Pembrolizumab Carboplatin + Cisplatin + Gemcitabine | Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) | Completed | 0 | |
| NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
| NCT02434354 | Phase I | Pembrolizumab | A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma | Completed | USA | 0 |
| NCT02955758 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT04462406 | Phase II | Pembrolizumab Nivolumab + Pembrolizumab Ipilimumab + Nivolumab Ipilimumab + Pembrolizumab Nivolumab | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | Recruiting | USA | 0 |
| NCT03757689 | Phase II | Pembrolizumab | Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma | Recruiting | USA | 0 |
| NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
| NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
| NCT04659811 | Phase II | Pembrolizumab | Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma | Recruiting | USA | 0 |
| NCT02879994 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT03694834 | Phase I | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer | Recruiting | USA | 0 |
| NCT04929041 | Phase II | Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | Recruiting | USA | 0 |
| NCT02641093 | Phase II | Cisplatin Pembrolizumab | Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT04134559 | Phase II | Pembrolizumab | Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | Recruiting | USA | 0 |
| NCT02576977 | Phase III | Pomalidomide Pembrolizumab Dexamethasone | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | Terminated | 0 | |
| NCT04987996 | Phase II | Pembrolizumab Belapectin + Pembrolizumab | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | Suspended | USA | 0 |
| NCT04201145 | Phase I | Pembrolizumab Defactinib + Pembrolizumab | Pembrolizumab + Defactinib In Pleural Mesothelioma | Withdrawn | USA | 0 |
| NCT05034536 | Phase II | Pembrolizumab Infliximab + Pembrolizumab | Pembrolizumab + Infliximab for Metastatic Melanoma | Recruiting | USA | 0 |
| NCT02362035 | Phase Ib/II | Acalabrutinib Pembrolizumab | ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145) | Active, not recruiting | USA | 0 |
| NCT04738487 | Phase III | Pembrolizumab Vibostolimab | Vibostolimab (MK-7684) With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003) | Recruiting | USA | CAN | 17 |
| NCT02852655 | Phase 0 | Pembrolizumab | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | Completed | USA | 0 |
| NCT02521870 | Phase I | Pembrolizumab SD-101 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma | Terminated | USA | DEU | 2 |
| NCT02325557 | Phase Ib/II | Pembrolizumab ADXS31-142 | ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046 | Unknown status | USA | 0 |
| NCT02819518 | Phase III | Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | Active, not recruiting | 0 | |
| NCT02362594 | Phase III | Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054) | Active, not recruiting | 0 | |
| NCT03506997 | Phase II | Pembrolizumab | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1) | Recruiting | 1 | |
| NCT03179917 | Phase II | Pembrolizumab | Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma | Recruiting | USA | 0 |
| NCT03304639 | Phase II | Pembrolizumab | Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer | Active, not recruiting | USA | 0 |
| NCT02637531 | Phase I | Pembrolizumab IPI-549 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | Active, not recruiting | USA | 0 |
| NCT02089685 | Phase Ib/II | Ipilimumab Peginterferon alfa-2b Pembrolizumab | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | Completed | 0 | |
| NCT02399371 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Malignant Mesothelioma | Active, not recruiting | USA | 0 |
| NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 9 |
| NCT03313804 | Phase II | Pembrolizumab Atezolizumab Nivolumab | Priming Immunotherapy in Advanced Disease With Radiation | Recruiting | USA | 0 |
| NCT02688608 | Phase II | Pembrolizumab | Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | Completed | USA | 0 |
| NCT02730546 | Phase Ib/II | Carboplatin + Paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT04747054 | Phase III | Pembrolizumab + Radiotherapy Pembrolizumab | Study on the Efficacy of Radiotherapy Added to Pembrolizumab in Newly Diagnosed Metastatic Head and Neck Cancers (PembroMetaRT) | Recruiting | FRA | 0 |
| NCT02301039 | Phase II | Pembrolizumab | A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | Completed | USA | 0 |
| NCT04332874 | Phase II | Pembrolizumab | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | Recruiting | USA | 0 |
| NCT03286114 | Phase I | Pembrolizumab | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Recruiting | USA | 0 |
| NCT05317858 | Phase III | Pembrolizumab | Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | Recruiting | USA | 0 |
| NCT03735290 | Phase Ib/II | Pembrolizumab Intuvax + Pembrolizumab | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) | Terminated | USA | 0 |
| NCT04995094 | Phase II | Pembrolizumab Pembrolizumab + PGG beta-glucan | Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | Withdrawn | USA | 0 |
| NCT03136055 | Phase II | Irinotecan + Pembrolizumab Paclitaxel + Pembrolizumab Pembrolizumab | Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas | Active, not recruiting | USA | 0 |
| NCT04547504 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % | Recruiting | FRA | 0 |
| NCT04897022 | Phase I | Pembrolizumab | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | Recruiting | USA | 0 |
| NCT04605614 | Phase I | Pembrolizumab | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | Withdrawn | 0 | |
| NCT02460198 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | Completed | 0 | |
| NCT03719105 | Phase I | Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | Recruiting | USA | 0 |
| NCT03287817 | Phase Ib/II | Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) | Active, not recruiting | USA | 1 |
| NCT03295227 | Phase I | Pembrolizumab | Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma | Unknown status | USA | 0 |
| NCT03833167 | Phase III | Pembrolizumab | Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 18 |
| NCT03469804 | Phase II | Pembrolizumab | Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma (KAPKEY) | Unknown status | FRA | 0 |
| NCT02730130 | Phase II | Pembrolizumab | Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | Active, not recruiting | USA | 0 |
| NCT02493361 | Phase II | Pembrolizumab IL-12 gene | Trial of pIL-12/MK-3475 in Metastatic Melanoma | Completed | USA | 0 |
| NCT02674061 | Phase II | Pembrolizumab | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | Completed | 0 | |
| NCT02752074 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 16 |
| NCT03237572 | Phase I | Pembrolizumab | Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48) | Terminated | USA | 0 |
| NCT04322643 | Phase II | Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Recruiting | USA | 0 |
| NCT02621021 | Phase II | Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin | A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | Recruiting | USA | 0 |
| NCT04675294 | Phase II | Evorpacept + Pembrolizumab Pembrolizumab | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | Recruiting | USA | ESP | CAN | BEL | 1 |
| NCT02632344 | Phase II | Pembrolizumab | Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement | Active, not recruiting | USA | 0 |
| NCT03486197 | Phase II | Pembrolizumab | Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma | Recruiting | USA | 0 |
| NCT03988647 | Phase II | Pembrolizumab | Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
| NCT03311672 | Phase II | Pembrolizumab | T-Cell PET Imaging With [18F]F-AraG in Lung Cancer | Withdrawn | 0 | |
| NCT02837263 | Phase I | Pembrolizumab | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
| NCT03976362 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Olaparib + Pembrolizumab | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | Active, not recruiting | USA | FRA | ESP | DEU | CAN | AUT | 14 |
| NCT03546582 | Phase II | Pembrolizumab | SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE) | Recruiting | USA | CAN | 0 |
| NCT02702414 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Active, not recruiting | 0 | |
| NCT02448303 | Phase II | Acalabrutinib Pembrolizumab | Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
| NCT02608385 | Phase I | Pembrolizumab | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03695471 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | Recruiting | USA | 0 |
| NCT04199104 | Phase III | Lenvatinib + Pembrolizumab Pembrolizumab | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 13 |
| NCT03072160 | Phase II | Pembrolizumab | Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer | Completed | USA | 0 |
| NCT02736266 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma | Recruiting | ITA | 0 |
| NCT03867084 | Phase III | Pembrolizumab | Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 24 |
| NCT02621151 | Phase II | Pembrolizumab Gemcitabine | Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder | Active, not recruiting | USA | 0 |
| NCT03793179 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | Recruiting | USA | CAN | 1 |
| NCT03698019 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery | Active, not recruiting | USA | 0 |
| NCT03311308 | Phase I | Metformin + Pembrolizumab Pembrolizumab | A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | Recruiting | USA | 0 |
| NCT03631706 | Phase II | M7824 Pembrolizumab | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 11 |
| NCT04375956 | Phase II | Pembrolizumab | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (MITO 27) | Recruiting | ITA | 0 |
| NCT03313206 | Phase II | Pembrolizumab | Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ) | Recruiting | FRA | 0 |
| NCT05075122 | Phase II | Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine Pembrolizumab | Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (FOCUS) | Recruiting | DEU | 0 |
| NCT02977468 | Phase I | Pembrolizumab | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) | Recruiting | USA | 0 |
| NCT02599779 | Phase II | Pembrolizumab | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients | Completed | CAN | 0 |
| NCT03634241 | Phase II | Pembrolizumab | Pembrolizumab in Treating Participants With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules | Recruiting | USA | 0 |
| NCT02499952 | Phase II | Pembrolizumab | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | Terminated | USA | 0 |
| NCT02906332 | Phase II | Pembrolizumab Dexamethasone | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | Active, not recruiting | USA | 0 |
| NCT05085028 | Phase III | Pembrolizumab | A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (REFINE-Lung) | Recruiting | 1 | |
| NCT04370509 | Phase II | Pembrolizumab Axitinib + Pembrolizumab | Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery | Recruiting | USA | 0 |
| NCT02504372 | Phase III | Pembrolizumab | Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) | Active, not recruiting | 0 | |
| NCT03732950 | Phase II | Pembrolizumab | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | Recruiting | USA | 0 |
| NCT02375672 | Phase II | Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | Completed | USA | 0 |
| NCT03189186 | Phase I | Pembrolizumab | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas | Withdrawn | USA | 0 |
| NCT03274661 | Phase II | Pembrolizumab | Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors | Active, not recruiting | USA | 0 |
| NCT04340258 | Phase Ib/II | Pembrolizumab | Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC | Recruiting | USA | 0 |
| NCT03004183 | Phase II | Pembrolizumab AdV-tk + Valacyclovir | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC | Active, not recruiting | USA | 0 |
| NCT02620423 | Phase I | Gemcitabine Fluorouracil Irinotecan Pelareorep Leucovorin Pembrolizumab | Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Completed | USA | 0 |
| NCT02658279 | Phase I | Pembrolizumab | Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype | Active, not recruiting | USA | 0 |
| NCT04188951 | Phase I | Pembrolizumab | HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer | Recruiting | USA | 0 |
| NCT03574220 | Phase I | Pembrolizumab | Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer | Withdrawn | 0 | |
| NCT02444741 | Phase Ib/II | Pembrolizumab | MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
| NCT03307759 | Phase I | Pembrolizumab | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) | Completed | CAN | 1 |
| NCT05173987 | Phase III | Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | Recruiting | USA | ITA | ESP | CAN | 17 |
| NCT03526887 | Phase II | Pembrolizumab | Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) | Recruiting | ESP | 0 |
| NCT04811027 | Phase II | Eftilagimod alpha + Pembrolizumab Pembrolizumab | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003) | Recruiting | USA | ESP | DEU | BEL | 4 |
| NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
| NCT02483247 | Phase Ib/II | Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Completed | USA | CAN | 0 |
| NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03914612 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Recruiting | USA | CAN | 3 |
| NCT03396471 | Phase II | Pembrolizumab | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | Active, not recruiting | USA | 0 |
| NCT03224871 | Phase I | Pembrolizumab Aldesleukin Nivolumab | A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | Completed | USA | 0 |
| NCT02775851 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT02255097 | Phase II | Pembrolizumab | Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | Completed | 0 | |
| NCT05488366 | Phase I | Pembrolizumab | Pembrolizumab Combined With Radiotherapy for Metastatic Sarcoma | Recruiting | USA | 0 |
| NCT05059470 | Phase II | Pembrolizumab | IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC | Recruiting | USA | 0 |
| NCT03241927 | Phase II | Pembrolizumab | Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | Terminated | USA | 0 |
CKB BOOST